Oxlumo is a medicine used for treating primary hyperoxaluria type 1, an inherited disease in which a substance called oxalate builds up in the body, causing damage to the kidneys and other organs. Oxlumo contains the active substance lumasiran. Primary hyperoxaluria is rare, and Oxlumo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 March 2016.
Therapeutic Indication
### Therapeutic indication Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
Therapeutic Area (MeSH)
ATC Code
A16AX18
ATC Item
lumasiran
Pharmacotherapeutic Group
Other alimentary tract and metabolism products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Lumasiran sodium | N/A | 奥卢莫 |
EMA Name
Oxlumo
Medicine Name
Oxlumo
Aliases
N/A
